1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
(
- Contribution to journal › Article
- 2023
-
Mark
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
(
- Contribution to journal › Article
- 2022
-
Mark
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
(
- Contribution to journal › Article
- 2021
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
(
- Contribution to journal › Article
- 2014
-
Mark
Monitoring of β-amyloid dynamics after human traumatic brain injury
(
- Contribution to journal › Article
- 2013
-
Mark
Functional Mannose-Binding Lectin Haplotype Variants are Associated with Alzheimer's Disease
(
- Contribution to journal › Article
- 2012
-
Mark
Evaluation of Plasma A beta as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study
(
- Contribution to journal › Article
-
Mark
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
(
- Contribution to journal › Article
- 2010
-
Mark
Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years.
(
- Contribution to journal › Article
-
Mark
Evaluation of plasma A beta(40) and A beta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
(
- Contribution to journal › Article